A Vaccine Booster (GEO-CM04S1) for the Prevention of COVID-19 in Patients With Chronic Lymphocytic Leukemia
Phase 2
80
about 2.5 years
18+
1 site in CA
What this study is about
This trial is testing a new vaccine, GEO-CM04S1, to see if it helps prevent COVID-19 infections in people with chronic lymphocytic leukemia. It compares this vaccine to the current standard of care vaccine and looks at whether the new vaccine boosts immunity better in patients with CLL.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1
- 2.Receive mRNA COVID-19 Vaccine
- 3.Undergo Biospecimen Collection
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
vaccine, Immunological Agents
injection
Secondary: Confirmed COVID-19 infection by PCR viral load, Incidence of AEs unacceptable toxicity (UT), Incidence of adverse events (AEs) moderate toxicity (MOD), Incidence of serious adverse events (SAEs), SARS-CoV-2-S and -N specific IFNgamma (Th1) and IL-4 (Th2) cytokine levels following stimulation with overlapping peptide libraries specific for SARS-CoV-2
diagnostic
Oncology, Infectious